Drug Profile
Japanese encephalitis vaccine - Mitsubishi Tanabe
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator BIKEN
- Developer Mitsubishi Tanabe Pharma Corporation
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Japanese encephalitis
Most Recent Events
- 01 Jan 2009 Launched for Japanese encephalitis in Japan (IM)